Rapid Micro Biosystems, a Bedford-based provider of automated microbial detection for quality control testing within the pharmaceutical and personal care products market segments, said Wednesday that it has raised $32.6 million in series B financing.
The funding will be used to expand the company’s commercial and manufacturing operations, the company said in a press release.
Longitude Capital and TPG Biotech led this financing round with continued participation from Kleiner Perkins Caufield & Byers, TVM Capital, and Quaker Partners.
According to the company, its Growth Direct platform is the only system on the market in which all applications can be run both concurrently and automatically on a single instrument. The system provides results starting within just hours, sending problem alerts so that decision-making and remedial action can start immediately.
‘‘These unique capabilities provide an attractive return on investment for our customers and getting drugs to market faster ultimately benefits patients,’’ company president and chief executive Steve Delity, said in a statement. ‘‘Our new investment partners, along with our current investors, position Rapid Micro Biosystems to meet the customer requirements for automated microbial detection and enumeration.’’